يعرض 1 - 20 نتائج من 2,403 نتيجة بحث عن '"Eudragit®"', وقت الاستعلام: 0.81s تنقيح النتائج
  1. 1
    Academic Journal
  2. 2
    Academic Journal
  3. 3
    Academic Journal
  4. 4
    Academic Journal

    المؤلفون: Patel, Jaymin1, 2, Patel, Kaushika1, Shah, Shreeraj1, 1

    المصدر: Research Journal of Pharmacy and Technology 17(4):1531-1536. 2024

  5. 5
    Academic Journal
  6. 6
    Academic Journal
  7. 7
    Academic Journal
  8. 8
    Academic Journal
  9. 9
    Academic Journal
  10. 10
    Academic Journal
  11. 11
    Academic Journal
  12. 12
    Academic Journal
  13. 13
    Academic Journal
  14. 14
    Academic Journal
  15. 15
    Academic Journal

    المؤلفون: Andayani, Regina, Hasbi, Febriyenti1

    المصدر: Research Journal of Pharmacy and Technology 16(11):5279-5284. 2023

  16. 16
    Academic Journal

    المؤلفون: Andiran, V.1, 1, Kannan, K.2

    المصدر: Research Journal of Pharmacy and Technology 16(3):1041-1046. 2023

  17. 17
    Academic Journal

    المصدر: Meditsinskiy sovet = Medical Council; № 15 (2024); 182–189 ; Медицинский Совет; № 15 (2024); 182–189 ; 2658-5790 ; 2079-701X

    وصف الملف: application/pdf

    Relation: https://www.med-sovet.pro/jour/article/view/8586/7541; Шелыгин ЮА, Ивашкин ВТ, Белоусова ЕА, Решетов ИВ, Маев ИВ, Ачкасов СИ и др. Язвенный колит (К51), взрослые. Колопроктология. 2023;22(1):10–44. https://doi.org/10.33878/2073-7556-2023-22-1-10-44.; Turner D, Ricciuto A, Lewis A, D’Amico F, Dhaliwal J, Griffiths AM et al.; International Organization for the Study of IBD. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 2021;160(5):1570–1583. https://doi.org/10.1053/j.gastro.2020.12.031.; Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(Suppl. A):5A–36A. https://doi.org/10.1155/2005/269076.; Truelove S, Witts L. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955;2:1041–1048. https://doi.org/10.1136/bmj.2.4947.1041.; Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625–1629. https://doi.org/10.1056/NEJM198712243172603.; Raine T, Bonovas S, Burisch J, Kucharzik T, Adamina M, Annese V et al. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. J Crohns Colitis. 2022;16(1):2–17. https://doi.org/10.1093/ecco-jcc/jjab178.; Reinisch W, Reinink AR, Higgins PD. Factors associated with poor outcomes in adults with newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol. 2015;13(4):635–642. https://doi.org/10.1016/j.cgh.2014.03.037.; Абдулганиева ДИ, Бакулев АЛ, Белоусова ЕА, Веселов АВ, Коротаева ТВ, Лила АМ и др. Раннее назначение генно-инженерных биологических препаратов при иммуновоспалительных заболеваниях: возможности и перспективы. Позиция экспертов. Альманах клинической медицины. 2020;48(6):422–436. https://doi.org/10.18786/2072-0505-2020-48-050.; Dias CC, Rodrigues PP, da Costa-Pereira A, Magro F. Clinical predictors of colectomy in patients with ulcerative colitis: systematic review and meta-analysis of cohort studies. J Crohns Colitis. 2015;9(2):156–163. https://doi.org/10.1093/ecco-jcc/jju016.; Feuerstein JD, Isaacs KL, Schneider Y, Siddique SM, Falck-Ytter Y, Singh S; AGA Institute Clinical Guidelines Committee. AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology. 2020;158(5):1450–1461. https://doi.org/10.1053/j.gastro.2020.01.006.; Ko CW, Singh S, Feuerstein JD, Falck-Ytter C, Falck-Ytter Y, Cross RK; American Gastroenterological Association Institute Clinical Guidelines Committee. AGA Clinical Practice Guidelines on the Management of Mildto-Moderate Ulcerative Colitis. Gastroenterology. 2019;156(3):748–764. https://doi.org/10.1053/j.gastro.2018.12.009.; Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK et al; IBD guidelines eDelphi consensus group, Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl. 3):s1-s106. https://doi.org/10.1136/gutjnl-2019-318484.; Ситкин СИ. Возможности повышения эффективности терапии и комплайенса у пациентов с воспалительными заболеваниями кишечника с помощью инновационных препаратов перорального месалазина. Гастроэнтерология Санкт-Петербурга. 2011;(1):2–5. Режим доступа: http://gastroforum.ru/wp-content/uploads/2013/06/GSP_1_2011_2-5.pdf.; Yamamoto Y, Masuda S, Nakase H, Matsuura M, Maruyama S, Hisamatsu T et al. Influence of Pharmaceutical Formulation on the Mucosal Concentration of 5-Aminosalicylic Acid and N-Acetylmesalamine in Japanese Patients with Ulcerative Colitis. Biol Pharm Bull. 2019;42(1):81–86. https://doi.org/10.1248/bpb.b18-00561.; D’Incà R, Paccagnella M, Cardin R, Pathak S, Baldo V, Giron MC, Sturniolo GC. 5-ASA colonic mucosal concentrations resulting from different pharmaceutical formulations in ulcerative colitis. World J Gastroenterol. 2013;19(34):5665–5670. https://doi.org/10.3748/wjg.v19.i34.5665.; Olaisen M, Spigset O, Flatberg A, Granlund AVB, Brede WR, Albrektsen G et al. Mucosal 5-aminosalicylic acid concentration, drug formulation and mucosal microbiome in patients with quiescent ulcerative colitis. Aliment Pharmacol Ther. 2019;49(10):1301–1313. https://doi.org/10.1111/apt.15227.; Murray A, Nguyen TM, Parker CE, Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2020;8(8):CD000543. https://doi.org/10.1002/14651858.CD000543.pub5.; D’Haens GR, Sandborn WJ, Zou G, Stitt LW, Rutgeerts PJ, Gilgen D et al. Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis. Aliment Pharmacol Ther. 2017;46(3):292–302. https://doi.org/10.1111/apt.14164.; Awadhi SA, Alboraie M, Albaba EA, Almutairdi A, Alsaad M, Azzam N et al. Treatment of Patients with Mild to Moderate Ulcerative Colitis: A Middle East Expert Consensus. J Clin Med. 2023;12(21):6929. https://doi.org/10.3390/jcm12216929.; Murray A, Nguyen TM, Parker CE, Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2020;8(8):CD000544. https://doi.org/10.1002/14651858.CD000544.pub5.; Белоусова ЕА, Халиф ИЛ, Абдулганиева ДИ, Алексеенко СА, Барановский АЮ, Валуйских ЕЮ и др. Социально-демографическая характеристика, особенности течения и варианты лечения воспалительных заболеваний кишечника в России. Результаты двух многоцентровых исследований. Альманах клинической медицины. 2018;46(5):445–463. https://doi.org/10.18786/2072-0505-2018-46-5-445-463.; Белоусова ЕА, Шелыгин ЮА, Ачкасов СИ, Хатьков ИЕ, Бакулин ИГ, Скалинская МИ и др. Клинико-демографические характеристики и лечебные подходы у пациентов с воспалительными заболеваниями кишечника (болезнь Крона, язвенный колит) в РФ. Первые результаты анализа национального Регистра. Колопроктология. 2023;22(1):65–82. https://doi.org/10.33878/2073-7556-2023-22-1-65-82.; Varma S, Hu J, Mehta A, Song Y, Park A, Zhi M, Hutfless S. Initial medical and surgical management of inflammatory bowel disease in the biologic era: A comparison between the United States and China. JGH Open. 2019;3(3):234–241. https://doi.org/10.1002/jgh3.12146.; Marti-Aguado D, Ballester MP, Tosca J, Bosca-Watts MM, Navarro P, Anton R et al. Long-term follow-up of patients treated with aminosalicylates for ulcerative colitis: Predictive factors of response: An observational casecontrol study. United European Gastroenterol J. 2019;7(8):1042–1050. https://doi.org/10.1177/2050640619854277.; Kane SV, Brixner D, Rubin DT, Sewitch MJ. The challenge of compliance and persistence: focus on ulcerative colitis. J Manag Care Pharm. 2008;14(1 Suppl.): s2-12;quizs13-5. https://doi.org/10.18553/jmcp.2008.14.s1-a.1a.; Loftus EV Jr. A practical perspective on ulcerative colitis: patients’ needs from aminosalicylate therapies. Inflamm Bowel Dis. 2006;12(12):1107–1113. https://doi.org/10.1097/01.mib.0000235831.01682.8d.; Franco FCZ, Oliveira MCC, Gaburri PD, Franco DCZ, Chebli JMF. High prevalence of non-adherence to ulcerative colitis therapy in remission: knowing the problem to prevent loss. Arq Gastroenterol. 2022;59(1):40–46. https://doi.org/10.1590/S0004-2803.202200001-08.; Gillespie D, Hood K, Farewell D, Stenson R, Probert C, Hawthorne AB. Electronic monitoring of medication adherence in a 1-year clinical study of 2 dosing regimens of mesalazine for adults in remission with ulcerative colitis. Inflamm Bowel Dis. 2014;20(1):82–91. https://doi.org/10.1097/01.MIB.0000437500.60546.2a.; Dignass A, Schnabel R, Romatowski J, Pavlenko V, Dorofeyev A, Derova J et al.; International SAT-25 Study Group. Efficacy and safety of a novel high-dose mesalazine tablet in mild to moderate active ulcerative colitis: a doubleblind, multicentre, randomised trial. United European Gastroenterol J. 2018;6(1):138–147. https://doi.org/10.1177/2050640617703842.; Sun J, Yuan Y. Mesalazine Modified-Release Tablet in the Treatment of Ulcerative Colitis in the Remission Phase: A Chinese, Multicenter, SingleBlind, Randomized Controlled Study. Adv Ther. 2016;33(3):410–422. https://doi.org/10.1007/s12325-016-0304-y.; Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390(10114):2769–2778. https://doi.org/10.1016/S0140-6736(17)32448-0.; Jeuring SF, van den Heuvel TR, Zeegers MP, Hameeteman WH, Romberg-Camps MJ, Oostenbrug LE et al. Epidemiology and Long-term Outcome of Inflammatory Bowel Disease Diagnosed at Elderly Age-An Increasing Distinct Entity? Inflamm Bowel Dis. 2016;22(6):1425–1434. https://doi.org/10.1097/MIB.0000000000000738.; Nguyen GC, Sheng L, Benchimol EI. Health Care utilization in elderly onset inflammatory bowel disease: a population-based study. Inflamm Bowel Dis. 2015;21(4):777–782. https://doi.org/10.1097/MIB.0000000000000306.; Ng SC, Tang W, Ching JY, Wong M, Chow CM, Hui AJ et al.; Asia – Pacific Crohn’s and Colitis Epidemiologic Study (ACCESS) Study Group. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn’s and colitis epidemiology study. Gastroenterology. 2013;145(1):158–165.e2. https://doi.org/10.1053/j.gastro.2013.04.007.; Sturm A, Maaser C, Mendall M, Karagiannis D, Karatzas P, Ipenburg N et al. European Crohn’s and Colitis Organisation Topical Review on IBD in the Elderly. J Crohns Colitis. 2017;11(3):263–273. https://doi.org/10.1093/ecco-jcc/jjw188.; Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lémann M, Cosnes J et al; CESAME Study Group. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374(9701):1617–1625. https://doi.org/10.1016/S0140-6736(09)61302-7.; Desai A, Zator ZA, de Silva P, Nguyen DD, Korzenik J, Yajnik V, Ananthakrishnan AN. Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(2):309–315. https://doi.org/10.1002/ibd.23026.; Белоусова ЕА, Никитина НВ, Цодикова ОМ. Лечение язвенного колита легкого и среднетяжелого течения. Фарматека. 2013;(2):42–46. Режим доступа: https://pharmateca.ru/en/archive/article/8718.; Мустафин РИ. Интраполимерные сочетания химически комплементарных типов сополимеров Eudragit как новое направление в создании пероральных систем доставки и лекарственных форм с модифицированным высвобождением. Химико-­фармацевтический журнал. 2011;45(5):38–39. Режим доступа: http://chem.folium.ru/index.php/chem/article/view/61/61#.; Минушкин ОН, Топчий ТБ, Евсиков АЕ, Пюрвеева КВ, Бурдина ЕГ, Скибина ЮС, Кручинина МЮ. Консервативная терапия язвенного колита легкого и среднетяжелого течения. Лечение и профилактика. 2022;12(3):101–105. Режим доступа: https://www.elibrary.ru/item.asp?edn=nvkgzv.; Шапина МВ. Месалазин в индукции клинико-эндоскопической ремиссии легких и среднетяжелых форм язвенного колита. Медицинский совет. 2022;16(15):90–97. https://elibrary.ru/nvkgzv.; Князев ОВ, Каграманова АВ, Лищинская АА, Парфенов АИ. Эффективность терапии месалазинами язвенного колита средней степени тяжести в реальной клинической практике. Медицинский совет. 2019;(14):80–86. https://doi.org/10.21518/2079-701X-2019-14-80-86.

  18. 18
    Academic Journal

    المساهمون: Department of Neurosciences, HUS Neurocenter, HUS Internal Medicine and Rehabilitation, Geriatrian yksikkö, Neurologian yksikkö

    وصف الملف: application/pdf

    Relation: Lombardo , R , Ruponen , M , Rautio , J , Ghelardini , C , Mannelli , L D C , Calosi , L , Bani , D , Lampinen , R , Kanninen , K M , Koivisto , A M , Penttilä , E , Lopponen , H & Pignatello , R 2023 , ' Development of Lyophilised Eudragit((R)) Retard Nanoparticles for the Sustained Release of Clozapine via Intranasal Administration ' , Pharmaceutics , vol. 15 , no. 5 , 1554 . https://doi.org/10.3390/pharmaceutics15051554; ff39bb5d-3604-44a8-968f-bd075de5bae2; http://hdl.handle.net/10138/572922; 000997249600001

  19. 19
    Academic Journal
  20. 20
    Academic Journal